BioSpace News Archive

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, and Alfonso Quintás-Cardama, M.D., Chief Medical Officer of TCR 2 Therapeutics, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 20

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company’s fourth quarter and full year 2020 financial results and provide an operational update on Thursday, February 25, 2021, at 7:30 a.m. ET.

EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, announces the signature of a strategic partnership with Onward Therapeutics.

Solution will provide new omnichannel marketing opportunities for retailer and its advertiser partners, and further increase consumer choice in saving with Quotient-powered promotions.

Nascent Biotech, Inc. a clinical-stage biotech company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce the publication of strong In-Vitro study results from its research collaboration with Syracuse University.

Havn Life Sciences Inc., announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately.

Stella Diagnostics, Inc. announced that they have entered into a Collaborative Research Agreement with the Mayo Clinic to assess the predictability and clinical utility of the Company’s STLA101 panel in patients diagnosed with Barrett’s esophagus.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2020, before the open of the financial markets on Wednesday, February 24, 2021.

The Get Iron Informed survey sheds light on knowledge of Iron Deficiency Anemia (IDA) - a condition that impacts one in five women of childbearing age